Pieris Pharmaceuticals In... (PIRS)
NASDAQ: PIRS
· Real-Time Price · USD
13.60
-2.51 (-15.58%)
At close: Dec 13, 2024, 10:00 PM
Pieris Pharmaceuticals Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -8.19M | -6.07M | -2.89M | -3.59M | -4.89M | -4.58M | -10.75M | 3.98M | -13.18M | -8.1M | -9.74M | -10.34M | -5.1M | -9.53M | -16.54M | -15.5M | -4.17M |
Depreciation & Amortization | n/a | 30K | n/a | n/a | -30K | -198K | 708K | 725K | 571K | 585K | 772K | 583K | 840K | 588K | 586K | 594K | 600K |
Stock-Based Compensation | 1.09M | -393K | 330K | 421K | 472K | 451K | 966K | 1.05M | 884K | 949K | 974K | 1.3M | 1.18M | 1.32M | 1.37M | 1.33M | 1.2M |
Other Working Capital | n/a | -556K | 1.77M | 2.19M | -3.41M | 21.11M | -15.52M | -18.89M | 591K | 851K | -451K | -7.29M | -19.95M | 9.72M | 56K | 43.46M | -9.76M |
Other Non-Cash Items | n/a | 3.92M | 932K | -503K | 1.83M | -748K | -19K | -182K | 125K | -384K | -337K | 123K | 91K | -56K | 40K | 27K | -41K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -253K | 14.89M | -106K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | n/a | n/a | 1.77M | 2.19M | -3.96M | -14.34M | -15.52M | -18.89M | 607K | -5.98M | -451K | -7.29M | -19.65M | -3.26M | 56K | 43.46M | -9.72M |
Operating Cash Flow | -6.77M | -2.51M | 146K | -1.48M | -7M | -19.67M | -9.72M | -13.43M | -11M | -12.93M | -8.78M | -15.58M | -22.64M | -10.94M | -14.48M | 29.91M | -12.14M |
Capital Expenditures | n/a | n/a | n/a | n/a | n/a | 13K | -69K | -67K | -48K | -1.01M | -34K | -629K | -389K | -342K | -350K | -229K | -28K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | -3.44M | 1.92M | 1.3M | -11.95M | n/a | -5.5M | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | -7.57M | -7.03M | -6.7M | -1.54M | -5.2M | -11.55M | -15.09M | -16.56M | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | -9M | -2.18M | 2.18M | 9M | 11M | 5.11M | 5.4M | 13.49M | 6.3M | 17.05M | 4.85M | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | -2.32M | 2.32M | 2.18M | 9M | 3.44M | -1.92M | -1.3M | 11.95M | 1.02M | 5.5M | -10.24M | -16.56M | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | -11.32M | 142K | 2.18M | 9M | 3.45M | -1.98M | -1.37M | 11.9M | 1.11M | 5.47M | -10.87M | -16.95M | -342K | -350K | -229K | -28K |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -1.2M | 87.09M | n/a | n/a | n/a | 14K | n/a | 52K | n/a | 93K | n/a | 114K | 85K | 235K | 566K | 1.21M | 20K |
Financial Cash Flow | -1.2M | 87.09M | n/a | n/a | n/a | 14K | n/a | 19.78M | n/a | 93K | 282K | 281K | 6.56M | 4.9M | 21.92M | 22.62M | 9.69M |
Net Cash Flow | -7.98M | 64.24M | -368K | 647K | 1.69M | -15.5M | -12.04M | 5.2M | 1.11M | -9.79M | -5.83M | -29.48M | -34.03M | -7.29M | 5.96M | 52.26M | -3.6M |
Free Cash Flow | -6.77M | -2.51M | 146K | -1.48M | -7M | -19.66M | -9.79M | -13.5M | -11.04M | -13.94M | -8.81M | -16.21M | -23.03M | -11.29M | -14.83M | 29.68M | -12.17M |